---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000116"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:44:18.011996+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds

## Summary
- Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.
- Modification 17 for CYFENDUS anthrax vaccine valued at $30.0M for delivery this year.
- Two options totaling $122.9M for VIGIV (smallpox complication) and BAT (botulism antitoxin) into early 2025.
- All awards from ASPR under existing 10-year contracts; reaffirms Emergent as trusted biodefense partner.

## SEC filing metadata
- accession: 0001367644-24-000116
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000116/0001367644-24-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000116/ebs-20240628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000116
- JSON: https://secwatch.observer/filing/0001367644-24-000116.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.